Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 23;14:1133207. doi: 10.3389/fimmu.2023.1133207

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Berz, Boughdad, Vietti-Violi, Digklia, Dromain, Dunet and Duran

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Immune-related hypophysitis in a 43-year-old female with cutaneous melanoma treated with ipilimumab and nivolumab. (A) Normal hypophyseal MRI performed 4 months prior to immunotherapy. After 3 cycles of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1), the patient developed headaches. (B) MRI revealed increased hypophyseal height with mild pituitary stalk thickening and reduced opto-chiasmatic cistern size compatible with hypophysitis (arrow). Ipilimumab was discontinued and 2 more cycles of nivolumab alone were administered. Eventually, nivolumab was discontinued due to a grade 3 toxidermia. (C) Hypophyseal MRI performed 3 months after the last immunotherapy cycle was normal with disappearance of signs of inflammation.